Beyond that defined clinical and therapeutic entity, further molecular exploration of MCT1 regulation and targeting might put forth new strategies to enhance cure rates of locally advanced unresectable HNSCC, a cancer entity whose treatment often results in unsatisfactory results. This evidence concerns the gene SLC16A1 and cancer.